Xtandi 40 MG capsule 120S
Ended Awarded
- Contract number
- SPE2DB25FQ62W
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,311
Award facts
- Contract value 100% obligated
- $4,311.35 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,311.35 by the Defense Logistics Agency on June 30, 2025, for the supply of Xtandi 40 mg capsules (120-count). This firm fixed-price delivery order, with an ultimate completion date of July 1, 2025, carries no set-aside designation and represents a continuation of the company's significant role in the federal pharmaceutical supply chain. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $499.9 billion vehicle valid through November 2026 that enables issuance of delivery orders for a comprehensive range of pharmaceutical products supporting Department of Defense healthcare facilities worldwide.
Xtandi is an oncology medication used in the treatment of certain prostate cancers, reflecting the scope of specialized pharmaceutical products that the Defense Logistics Agency procures to support military health facilities. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical distribution network, leveraging its woman-owned small business status to compete effectively while maintaining a robust portfolio of delivery orders covering everything from contraceptive devices to specialized cancer treatments and vaccines. The company's continued awards under this program demonstrate sustained demand for its pharmaceutical distribution services across the Department of Defense healthcare system.
Quick answers
Who was awarded contract SPE2DB25FQ62W?
SPE2DB25FQ62W was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on June 30, 2025.
How much is contract SPE2DB25FQ62W worth?
The government has obligated $4,311 on SPE2DB25FQ62W.
Is contract SPE2DB25FQ62W an order under another contract?
Yes. SPE2DB25FQ62W is a delivery order under SPE2DB20D9226, an indefinite delivery contract.
Was contract SPE2DB25FQ62W competed?
The extent of competition for SPE2DB25FQ62W was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award